Nonalcoholic steatohepatitis (NASH) is a growing clinical concern, but currently there is no approved medicine for treatment of NASH. Fibroblast growth...
Gender Related Differences and Pregnancy Induced Changes in Labetalol Glucuronidation Assessed via PBPK Modeling and Simulation
Glucuronidation is considered a major metabolic pathway for drugs containing carboxylic acid, hydroxyl, and amine moieties [1].
Applicability of Existing Prediction Methods to Non-Oral Routes of Delivery
Discuss advances made with PBPK modeling for both oral and non-oral routes for the first in human predictions
MIDD in Preclinical Drug Development
Providing a case for why you should focus on preclinical verification when using Physiologically Based Pharmacokinetic (PBPK) modeling for First-In-Human (F.I.H) pharmacokinetic predictions.
Predicting the Efficacy of Obeticholic Acid Treatment for Non-Alcoholic Steatohepatitis (NASH) Using NAFLDsym, a Quantitative Systems Pharmacology Model of Non-Alcoholic Fatty Liver Disease
Obeticholic acid (OCA), a bile acid analog and agonist of the farnesoid X receptor (FXR), is currently in clinical trials...
Deep eutectic liquid as transdermal delivery vehicle of Risperidone
The work outlined herein describes an evaluation of a green solvent working as a drug solubility and penetration enhancer made up of a deep eutectic system (DES) composed of menthol (MN) and capric acid (CA).